Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.
Recently, the Premium Times, a Nigerian news source, reported on a potential health crisis facing up to 50 million Nigerian citizens: onchocerciasis, or river blindness. Onchocerciasis is considered a "neglected…
If you're like me, you've probably been listening to a lot of podcasts over this past year while stuck at home or in quarantine. While my typical podcast selection centers…
What if there was a way to genetically prevent the development of certain conditions, such as Alzheimer's disease? According to Medical XPress, this might soon be an option on the…
Just around a month ago, the National Organization for Rare Disorders (NORD) offered a webinar on how to create a patient registry or start a nonprofit organization. NORD's webinar, part…
Recently, Business Insider reported on published, peer-reviewed results following the Adaptive COVID-19 Treatment Trial (ACTT-2). The Phase 3 clinical trial, sponsored by the National Institute of Allergy and Infectious Diseases…
As the medical field expands, so do the options for new and intriguing medical research. According to Drug Target Review, researchers from the University of California (UC) San Diego…
In early December 2020, the American Society of Hematology (ASH) held their Annual Meeting and Exposition. During the meeting, many companies presented data on clinical trials and treatments related…
For years, researchers questioned how molecular changes in our bodies can contribute to, or perhaps fight, depression. According to Medical Xpress, this answer may soon be available. Researchers from UT…
In a recent press release, Kite, a biopharmaceutical company that is part of Gilead Sciences, announced one-year follow-up results from the ZUMA-2 clinical trial. Within the trial, researchers evaluated Tecartus…
According to Healio, there is now another health-related issue that can cause more hospitalization and worse quality of life (QOL) in patients with pulmonary arterial hypertension (PAH): obesity. In the…
Since its conception, biopharmaceutical company Geron Corporation ("Geron") has worked to develop first-in-class therapies for hematologic myeloid malignancies. More recently, Geron began evaluating imetelstat for patients with lower risk myelodysplastic syndromes…
Admittedly, 2020 has been tough for a variety of reasons. One of the greatest? The spread of COVID-19, a novel coronavirus attributed to 72.8 million cases and 1.62 million deaths…
Currently, there are a host of health-related issues associated with diabetes. One specific health problem, which currently represents an unmet need, is pain associated with diabetic peripheral neuropathy. According to…
According to a recent press release, oncology company Novocure enrolled its first patient in a Phase 3 clinical trial to evaluate Optune, alongside radiation therapy, for patients with newly diagnosed…
Did you know that zebrafish, a tropical freshwater fish, are being more commonly used to model and study human diseases? Now, says Phys.org, researchers from the Garvan Institute of Medical…
In a recent press release, biopharmaceutical company Acceleron Pharma, Inc. ("Acceleron") announced that its investigational drug candidate sotatercept received Orphan designation from the European Commission (EC) for the treatment of…
In early December 2020, biopharmaceutical company Gilead Sciences, Inc. ("Gilead") shared updated results from a Phase 1b clinical trial evaluating magrolimab for patients with treatment-naïve acute myeloid leukemia (AML). Generally,…
If you've ever heard the term "levodopa" be discussed, it was probably in regards to Parkinson's disease. Currently, levodopa (L-DOPA) is the most commonly prescribed therapy for patients with Parkinson's.…
In early December 2020, mRNA medicines company Arcturus Therapeutics Holdings Inc. ("Arcturus") announced that the company begun dosing participants within its Phase 1b clinical trial. Within the trial, researchers will…
For most of 2020, the coronavirus pandemic has dominated the headlines. What began earlier this year has transformed into a viral crisis with 69.8 million cases worldwide. To stifle the…
In a recent press release, biotechnology company HemoShear Therapeutics ("HemoShear") shared that the company, in collaboration with Takeda Pharmaceutical Company Ltd. ("Takeda") identified a novel therapeutic target for nonalcoholic steatohepatitis…
When Camden Rau was born, his parents immediately knew that he was facing some sort of health problem. According to Camden's father, Steven, who spoke to Wink News, Camden's skull…
Over the last decade, more information has been discovered about sudden unexpected death in epilepsy (SUDEP), although there is still much learning to be done. While researchers initially believed…
According to Fragile X News Today, a new registry recently launched within the United States to spur research into gene premutations linked to fragile X syndrome (FXS). Currently, the…
On November 27, biotechnology company Vertex Pharmaceuticals Inc. ("Vertex") announced the approval of SYMKEVI with KALYDECO for the treatment of pediatric patients with cystic fibrosis (CF), says GuruFocus. The…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
